Abstract
The proto-oncogene c-myc is involved in regulating proliferation and apoptosis, and its deregulation via genomic and postgenomic mechanisms, contributes to the development and progression of multiple human cancers, including those of the breast. Deregulated expression of c-Myc also contributes to neoplastic transformation by altering cellular differentiation pathways and by facilitating mutagenesis through induction of genomic instability. Transgenic and gene-knockout mice are frequently utilized to resolve the mechanisms through which specific genes influence the development and progression of malignancies. In this review, we discuss how research findings obtained from various c-myc transgenic mammary tumor models help to improve our resolution of c-Myc's role both in tumorigenesis of the murine mammary gland and cancer of the human breast.
Similar content being viewed by others
REFERENCES
P. Devilee and C. J. Cornelisse (1994). Somatic genetic changes in human breast cancer. Acta Biochim. Biophys. 1198:113–130.
D. W. Visscher, T. Wallis, S. Awussah, A. Mohamed, and J. D. Crissman (1997). Evaluation of Myc and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer 18:1–7.
T. Ried, K. E. Just, H. Hotlgreve-Grez, S. du Manoir, M. R. Speicher, E. Schröck, C. Latham, H. Blegen, A. Zetterberg, and T. Cremer (1995). Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res. 55:5415–5423.
M. Tirkkonen, M. Tanner, R. Karhu, A. Kallioniemi, J. Isola, and O. P. Kallioniemi (1998). Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177–184.
R. D. Cardiff, M. R. Anver, B. A. Gusterson, L. Hennighausen, R. A. Jensen, M. J. Merino, S. Rehm, J. Russo, F. A. Tavassoli, L. M. Wakefield, J. M. Ward, and J. E. Green (2000). The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene 19:968–988.
R. D. Cardiff and S. R. Wellings (1999). The comparative pathology of human and mouse mammary glands. J. Mammary Gland Biol. Neoplasia 4:105–122.
B. Vennstrom, D. Sheiness, J. Zabielski, and J. M. Bishop (1982). Isolation and characterization of c-Myc, a cellular homolog of the oncogene (v-Myc) of the avian myelocytomatosis virus strain 29. J. Virol. 42:773–779.
S. K. Oster, C. S. W. Ho, E. L. Soucie, and L. Z. Penn (2002). The myc oncogene: Marvelously complex. Adv. Cancer Res. 84:81–154.
C. V. Dang (1999). c-Myc target genes involved in cell growth, apoptosis and metabolism. Mol. Cell. Biol. 19:1–11.
M. H. Jamerson, M. D. Johnson, and R. B. Dickson (2000). Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene 19:1065–1071.
C. Escot, C. Theillet, R. Lidereau, F. Spyratos, M. H. Champeme, K. Gest, R. Callahan (1986). Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. U.S.A. 83:4834–4838.
D. J. Liao and R. B. Dickson (2000). c-myc in breast cancer. Endocr. Relat. Cancer 7:143–164.
S. L. Deming, S. J. Nass, R. B. Dickson, and B. J. Trock (2000). c-Myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance. Br. J. Cancer 83:1688–1695.
L. E. Janocko, K. A. Brown, C. A. Smith, L. P. Gu, A. A. Pollice, S. G. Singh, T. Julian, N. Wolmark, L. Sweeney, J. F. Silverman, and S. E. Shackney (2001). Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers. Cytometry 46:136–149.
C. X. Deng and F. Scott (2000). Role of tumor suppressor gene brca1 in genetic stability and mammary gland tumor formation. Oncogene 19:1059–1064.
G. A. Doyle, J. M. Bordeau-Heller, S. Coulthard, L. F. Meisner, and J. Ross (2000). Amplification in human breast cancer of a gene encoding a c-myc mRNA binding protein. Cancer Res. 60:2756–2759.
P. Ioannidis, L. Mahaira, A. Papadopoulou, M. R. Teixeira, S. Heim, J. A. Andersen, E. Evangelou, U. Dafni, N. Pandis, and T. Trangas (2003). 8q24 copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. Int. J. Cancer 104:54–59.
N. E. Hynes and H. A. Lane (2001). Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. J. Mammary Gland Biol. Neoplasia 6:141–150.
K. A. Waite and C. Eng (2002). Protean PTEN: Form and function. Am. J. Hum. Genet. 70:829–844.
R. Sears, G. Lone, J. DeGregori, and J. R. Nevins (1999). Ras enhances Myc protein stability. Mol. Cell 3:169–179.
M. J. West, M. Stoneley, and A. E. Willis (1998). Translational induction of the c-myc oncogene via activation of the FRAP/TOR signaling pathway. Oncogene 17:769–780.
T. A. Stewart, P. K. Pattengale, and P. Leder (1984). Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38:627–637.
C. A. Schoenenberger, A. C. Andres, B. Groner, M. van der Valk, M. LeMeur, and P. Gerlinger (1988). Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J. 7:169–175.
E. P. Sandgren, J. A. Schroeder, T. H. Qui, R. D. Palmiter, R. L. Brinster, and D. C. Lee (1995). Inhibition of mammary gland involution is associated with transforming growth factor α but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res. 55:3915–3927.
C. M. D'Cruz, E. J. Gunther, R. B. Boxer, J. L. Hartman, L. Sintasath, S. E. Moody, J. D. Cox, S. I. Ha, G. K. Belka, A. Golant, R. D. Cardiff, and L. A. Chodosh (2001). c-Myc induces mammary tumorigenesis by means of a preferred pathway involving spontaneous kras2 mutations. Nat. Med. 7:235–239.
L. A. Donehower, A. L. Huang, and G. L. Hager (1981). Regulatory and coding potential of the mouse mammary tumor virus long terminal redundancy. J. Virol. 37:226–238.
A. Leder, P. K. Pattengale, A. Kuo, T. A. Stewart, and P. Leder (1986). Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development. Cell 45:485–495.
E. Sinn, W. Muller, P. Pattengale, I. Tepler, R. Wallace, and P. Leder (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465–475.
R. D. Cardiff, E. Sinn, W. Muller, and P. Leder (1991). Transgenic oncogenic mice: Tumor phenotype predicts genotype. Am. J. Pathol. 139:495–501.
L. T. Amundadottir, M. D. Johnson, G. Merlino, G. H. Smith, and R. B. Dickson (1995). Synergistic interaction of transforming growth factor α and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ. 6:737–748.
D. J. Bearss, R. J. Lee, D. A. Troyer, R. G. Pestell, and J. J. Windle (2002). Differential effects of p21WAF1/CIP1 deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res. 62:2077–2084.
Z. A. Weaver, S. J. McCormack, M. Liyanage, du S. Manoir, A. Coleman, E. Schröck, R. B. Dickson, and T. Ried (1999). A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-c-myc transgenic mice. Genes Chromosomes Cancer 25:251–260.
C. J. Der, T. G. Krontiris, and G. M. Cooper (1982). Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl. Acad. Sci. U.S.A. 79:3637–3640.
M. Macaluso, G. Russo, C. Cinti, V. Bazan, N. Gebbia, and A. Russo (2002). Ras family genes: an interesting link between cell cycle and cancer. J. Cell. Physiol. 192:125–130.
S. Miyakis, G. Sourvinos, and D. A. Spandidos (1998). Differential expression and mutation of the ras family of genes in human breast cancer. Biochem. Biophys. Res. Commun. 251:609–612.
H. Land, L. F. Parada, and R. A. Weinberg (1983). Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596–602.
R. Jäger, U. Herzer, J. Schenkel, and H. Weiher (1997). Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 15:1787–1795.
S. J. McCormack, Z. Weaver, S. Deming, G. Natarajan, J. Torri, M. D. Johnson, M. Liyanage, T. Ried, and R. B. Dickson (1998). Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene 16:2755–2766.
A. Elson, C. Deng, J. Campos-Torres, L. A. Donehower, and P. Leder (1995). The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 11:181–190.
J. E. Hundley, S. K. Koester, D. A. Troyer, S. G. Hilsenbeck, R. E. Barrington, and J. J. Windle (1997). Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Res. 57:600–603.
A. L. Schechter, D. F. Stern, L. Vaidyanathan, S. J. Decker, J. A. Drebin, M. I. Green, and R. A. Weinberg (1984). The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516.
D. L. Dankort and W. J. Muller (2000). Signal transduction in mammary tumorigenesis. Oncogene 19:1038–1044.
S. Jepson, M. Komatsu, B. Haq, M. E. Arango, D. Huang, C. A. Carraway, and K. L. Carraway (2002). Muc4/sialomucin complex, the intermembrane erbB2 ligand, induces specific phosphorylation of erbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinase B/Akt pathways. Oncogene 21:7524–7532.
T. Cooke, J. Reeves, A. Lanigan, and P. Stanton (2001). HER2 as a prognostic and predictive marker for breast cancer. Ann. Oncol. 12:S23–S28.
W. J. Muller, E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder (1988). Single-step induction of mammary adenocarcinomas in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115.
C. T. Guy, M. A. Webster, M. Schaller, T. J. Parsons, Cardiff, and W. J. Muller (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U.S.A. 89:10578–10582.
Y. Tsujimoto, J. Cossman, E. Jaffe, and C. M. Croce (1985). Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440–1443.
Y. Tsujimoto (1998). Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cell 3:697–707.
C. F. Lincz (1998). Deciphering the apoptotic pathway: All roads lead to death. Immunol. Cell Biol. 76:1–19.
J. M. Zapata, M. Krajewska, S. Krajewski, R. P. Huang, S. Takayama, H. G. Wang, E. Adamson, and J. C. Reed (1998). Expression of multiple apoptotic-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res. Treat. 47:129–140.
S. Krajewski, M. Krajewska, B. C. Turner, C. Pratt, B. Howard, J. M. Zapata, V. Frenkel, S. Robertson, Y. Ionov, H. Yamamoto, M. Perucho, S. Takayama, and J. C. Reed (1999). Prognostic significance of apoptosis regulators in breast cancer. Endocr. Relat. Cancer 6:29–40.
A. Shilkaitis, J. Graves, R. R. Mehta, L. Hu, M. You, V. Steele, G. Kelloff, and K. Christov (2000). Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant and malignant lesions of mammary carcinogenesis. Cell Growth Differ. 11:437–445.
K. Schorr, M. Li, U. Bar, Peled, A. Lewis, A. Heredia, B. Lewis, C. M. Knudson, S. J. Korsmeyer, R. Jäger, H. Weiher, and P. A. Furth (1999). Gain of Bcl-2 is more potent that Bax loss in regulating mammary epithelial cell survival in vivo. Cancer Res. 59:2541–2545.
I. Martinez-Lacaci, C. Bianco, M. De Santis, and D. S. Salomon (1999). Epidermal growth factor-related peptides and their cognate receptors in breast cancer. In: A. M. Bowcock, (ed.) Breast Cancer: Molecular Genetics, pathogenesis, and therapeutics, Vol. 1, Humana Press, Totowa NJ, pp. 31–57.
L. V. Crawford, D. C. Pim, E. G. Gurney, P. Goodfellow, and J. Taylor-Papdimitriou (1981). Detection of a common feature in several human tumor cell lines—A 53,000-dalton protein. Proc. Natl. Acad. Sci. U.S.A. 78:41–45.
W. S. El-Deiry (1998). Regulation of p53 downstream genes. Semin. Cancer Biol. 8:345–357.
D. Medina, F. S. Kittrell, A. Shepard, L. C. Stephens, C. Jiang, J. Lu, D. C. Allred, M. McCarthy, and R. L. Ullrich (2002). Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J. 16:881–883.
J. W. Harper, G. Adami, N. Wei, K. Keyomarsi, and S. Elledge (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816.
W. S. El-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin W. E. Mercer, K. W. Kinzler, and B. Vogelstein (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
C. J. Sherr and J. M. Roberts (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512.
A. L. Gartel and A. L. Tyner (2002). The role of the cyclindependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1:639–649.
K. V. Desai, N. Xiao, W. Wang, L. Gangi, J. Greene, J. I. Powell, R. B. Dickson, P. A. Furth, K. Hunter, R. Kucherlapati, R. Simon, E. T. Liu, and J. E. Green (2002). Initiating oncogenic events determine gene-expression patterns of human breast cancer models. Proc. Natl. Acad. Sci. U.S.A. 99:6967–6972.
M. H. Jamerson, M. D. Johnson, P. A. Furth, S. J. Korsmeyer, G. Nunez, and R. B. Dickson (2001). Gain of bcl-x L and loss of bax cooperate in c-myc-mediated mammary tumorigenesis, Keystone Symposium: Molecular Mechanisms of Apoptosis, Abstract #239.
R. K. Sypniewska, L. Hoflack, D. J. Bearss, and C. Gravecamp (2002). Potential mouse tumor model for pre-clinical testing of MAGE-specific breast cancer vaccines. Breast Cancer Res. Treat. 74:221–233.
M. S. Noble, E. C. Rosfjord, R. Sharp, G. Merlino, and R. B. Dickson (2002). Ectopic VEGF expression promotes metastasis in a bitransgenic breast cancer model. Era of Hope Department of Defense Breast Cancer Research Program, Abstract P9-7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jamerson, M.H., Johnson, M.D. & Dickson, R.B. Of Mice and Myc: c-Myc and Mammary Tumorigenesis. J Mammary Gland Biol Neoplasia 9, 27–37 (2004). https://doi.org/10.1023/B:JOMG.0000023586.69263.0b
Issue Date:
DOI: https://doi.org/10.1023/B:JOMG.0000023586.69263.0b